| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 83.4 | 83.4 | -43.6 | -76.9 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 28,773.2 | 24,157.4 | 20,517.8 | 18,413.1 |
Net Worth | 28,856.6 | 24,240.8 | 20,474.2 | 18,336.2 |
Minority Interest | ||||
Debt | 3,492.9 | 792.9 | 50.8 | 2,205.4 |
Deferred Tax Liability Net | 609.9 | 511.2 | 339.2 | 422.2 |
Total Liabilities | 32,959.4 | 25,544.9 | 20,864.2 | 20,963.8 |
Fixed Assets | 10,429.2 | 8,800.1 | 8,119.7 | 7,350.8 |
Intangible Assets | ||||
Investments | 13,193.5 | 7,320.6 | 7,440 | 4,936.7 |
Deferred Tax Asset Net | 94.5 | 95.1 | 0 | 441.6 |
Networking Capital | 8,265.4 | 8,112.2 | 4,658.7 | 6,204.2 |
Inventories | 4,575.8 | 4,018.9 | 3,043 | 3,347.8 |
Inventory Days | 84.82 | |||
Sundry Debtors | 5,959 | 4,623.9 | 4,288.9 | 4,945.4 |
Debtor Days | 125.3 | |||
Other Current Assets | 3,156.6 | 4,378.9 | 1,837.4 | 1,865 |
Sundry Creditors | -2,515.2 | -2,432.3 | -2,094.6 | -1,927.7 |
Creditor Days | 48.84 | |||
Other Current Liabilities | -2,910.8 | -2,477.2 | -2,416 | -2,026.3 |
Cash | 976.8 | 1,216.9 | 645.8 | 2,030.5 |
Total Assets | 32,959.4 | 25,544.9 | 20,864.2 | 20,963.8 |
The capital was infused via cash and will be used to support DRL Russia’s working capital requirements.
As per the terms agreement, Alvotech and Dr Reddy’s will jointly develop and manufacture the biosimilar candidate and share costs and responsibilities.
Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.
The board has recommended a final dividend of ₹8 per equity share for FY 2024–25
Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
